Turn this role into an interview — a resume and cover letter built around what this employer wants.
NTNU is seeking a researcher in computational high-content imaging analysis to work on ERKetype project. You will analyze Cell Painting data from cancer models and develop reproducible Python pipelines to link imaging phenotypes with drug responses, collaborating with international partners.
The role requires a PhD and strong English, with opportunities to publish and contribute to consortium deliverables in a cutting-edge precision oncology setting.
NTNU is a broad-based university with atechnical-scientific profile and a focusin professional education. The university is located in three cities with headquarters in Trondheim.
At NTNU, 9,000 employees and 43,000 students work to create knowledge for a better world.
You can find more information about working at NTNU and the application process here.
Are you excited by the possibility of turning cellular imaging, drug-response data and cancer biology into better treatment predictions for individual patients? We have a two-year position for a researcher in computational high-content imaging analysis as part of the international EP PerMed project ERKetype.
ERKetype aims to develop digital twins as complex biomarkers for precision cancer medicine, with a particular focus on cancers driven by dysregulation of the RAS/RAF/MEK/ERK signalling pathway. The project combines patient-derived cancer models, Cell Painting and other high-content imaging approaches, pharmaco-proteomics, multi-omics data, artificial intelligence and mechanism-based modelling to understand why cancer cells respond - or fail to respond - to targeted therapies.
The researcher will be part of FlobakLab at NTNU (www.flobaklab.com), an interdisciplinary precision oncology group with expertise in both wet- and dry-lab research. In this position, you will play a central role in analysing Cell Painting and high-content imaging data from drug screens in cancer cell lines, patient-derived cancer organoids and patient-derived tumouroids. You will work closely with SINTEF Industry and its robotic high-throughput drug-screening facilities. The researcher will also have access to FlobakLab’s dedicated GPU workstation, equipped with 4 × RTX PRO 6000 Max-Q GPUs and supported by NVIDIA. Your work will include developing reproducible Python-based analysis pipelines, extracting and interpreting morphological drug-response signatures, and developing and implementing approaches to integrate imaging-derived phenotypes with mechanistic and knowledge-driven modelling frameworks.
This is an opportunity to work at the interface between computational biology, cancer systems medicine and translational precision oncology. You will collaborate closely with experimental, computational and clinical partners in Norway and internationally.
The position is well suited for a motivated researcher who wants to develop advanced imaging-data methods and apply them to clinically relevant questions in personalised cancer medicine.
Your immediate leader is Professor Åsmund Flobak.
As a researcher (code 1109) you are normally paid from gross NOK 600 000 to NOK 730 000per annum before tax, depending on qualifications and seniority. As required by law, 2% of this salary will be deducted and paid into the Norwegian Public Service Pension Fund.
The engagement is to be made in accordance with the regulations in force concerningState Employees and Civil Servants , and the acts relating to Control of the Export of Strategic Goods, Services and Technology. Candidates who by assessment of the application and attachment are seen to conflict with the criteria in the latter law will be prohibited from recruitment to NTNU.
After the appointment you must assume that there may be changes in the area of work.
For the necessary professional and social interaction, it is a prerequisite that you are physically present and available to the institution on a daily basis.
If you have any questions regarding the position, please contact Professor Åsmund Flobak, tel. 0047 72 57 37 17, e-mail asmund.flobak@ntnu.no.
If you have questions regarding the recruitment process, please contact HR Advisor Sissel Sollien, e-mail sissel.sollien@ntnu.no
Located in central Norway, Trondheim is a dynamic and forward‑looking city known for its strong research, technology, and innovation ecosystem. With a population of around 200,000, the city combines the advantages of urban living with easy access to nature. Residents benefit from Norway’s high standard of living and comprehensive welfare system, including excellent healthcare, education, and affordable childcare. Trondheim offers a vibrant cultural scene, outstanding opportunities for families, including international schools, and a safe and welcoming community with low crime rates, clean air, and easy access to outdoor activities year‑round.
NTNU - knowledge for a better world
The Norwegian University of Science and Technology (NTNU) creates knowledge for a better world and solutions that can change everyday life.
The Department of Clinical and Molecular Medicine (IKOM):
The Department of Clinical and Molecular Medicine (IKOM) is NTNU’s largest department, with 450 employees. Our research and teaching help to improve treatment and health.
IKOM has expertise in basic, clinical and translational research within broad disciplinary areas. We study children’s and women’s health, cancers, blood disorders and infectious diseases, gastroenterology, inflammation, metabolic disorders, laboratory sciences and medical ethics. The Department offers teaching in medicine at master’s and PhD level. We also offer continuing education for employees in the health services.